Vicinitas Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vicinitas Therapeutics - overview
Established
2022
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2022, Vicinitas Therapeutics operates as a biotechnology company that develops small-molecule drugs. The company was founded by Dan Nomura. In July 2022, Vicinitas Therapeutics raised USD 65 million in series A funding co-led by Andreessen Horowitz, Deerfield Management, Berkeley Catalyst Fund, and DROIA Ventures. Vicinitas Therapeutics offers Deubiquitinase Targeting Chimera (DUBTAC), which is a targeted protein stabilization (TPS) platform that is focused on many diseases that are driven by proteins, which include cancer and monogenic diseases.
The company's TPS platform provides development based on heterobifunctional small molecules, which contain an OTUB1 recruiter for the deubiquitinase and a ligand that targets proteins.
Current Investors
GV, Andreessen Horowitz, Deerfield Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.vicinitastx.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.